866-997-4948(US-Canada Toll Free)

Neurotoxicity Syndromes Global Clinical Trials Review, H2, 2015

Published By :

GlobalData

Published Date : Dec 2015

Category :

Pharmaceutical

No. of Pages : 72 Pages

Neurotoxicity Syndromes Global Clinical Trials Review, H2, 2015

Summary

GlobalData's clinical trial report, Neurotoxicity Syndromes Global Clinical Trials Review, H2, 2015" provides an overview of Neurotoxicity Syndromes clinical trials scenario. This report provides top line data relating to the clinical trials on Neurotoxicity Syndromes. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalDatas proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Report Guidance 5
Clinical Trials by Region 6
Clinical Trials and Average Enrollment by Country 7
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Countries Contributing to Clinical Trials in Middle East and Africa 13
Clinical Trials by G7 Countries: Proportion of Neurotoxicity Syndromes to Central Nervous System Clinical Trials 14
Clinical Trials by Phase in G7 Countries 15
Clinical Trials in G7 Countries by Trial Status 16
Clinical Trials by E7 Countries: Proportion of Neurotoxicity Syndromes to Central Nervous System Clinical Trials 17
Clinical Trials by Phase in E7 Countries 18
Clinical Trials in E7 Countries by Trial Status 19
Clinical Trials by Phase 20
In Progress Trials by Phase 21
Clinical Trials by Trial Status 22
Clinical Trials by End Point Status 23
Subjects Recruited Over a Period of Time 24
Clinical Trials by Sponsor Type 25
Prominent Sponsors 26
Top Companies Participating in Neurotoxicity Syndromes Therapeutics Clinical Trials 27
Prominent Drugs 28
Clinical Trial Profile Snapshots 29
Appendix 69
Abbreviations 69
Definitions 69
Research Methodology 70
Secondary Research 70
About GlobalData 71
Contact Us 71
Disclaimer 71
Source 72

List of Tables
Neurotoxicity Syndromes Therapeutics, Global, Clinical Trials by Region, 2015* 6
Neurotoxicity Syndromes Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2015* 8
Neurotoxicity Syndromes Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2015* 9
Neurotoxicity Syndromes Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2015* 10
Neurotoxicity Syndromes Therapeutics Clinical Trials, Europe, Top Five Countries, 2015* 11
Neurotoxicity Syndromes Therapeutics Clinical Trials, North America, Top Countries, 2015* 12
Neurotoxicity Syndromes Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2015* 13
Proportion of Neurotoxicity Syndromes to Central Nervous System Clinical Trials, G7 Countries (%), 2015* 14
Neurotoxicity Syndromes Therapeutics, G7 Countries, Clinical Trials by Phase, 2015* 15
Neurotoxicity Syndromes Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2015* 16
Proportion of Neurotoxicity Syndromes to Central Nervous System Clinical Trials, E7 Countries (%), 2015* 17
Neurotoxicity Syndromes Therapeutics, E7 Countries, Clinical Trials by Phase, 2015* 18
Neurotoxicity Syndromes Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2015* 19
Neurotoxicity Syndromes Therapeutics, Global, Clinical Trials by Phase, 2015* 20
Neurotoxicity Syndromes Therapeutics, Global, Clinical Trials In Progress by Phase 2015* 21
Neurotoxicity Syndromes Therapeutics, Global, Clinical Trials by Trial Status, 2015* 22
Neurotoxicity Syndromes Therapeutics Clinical Trials, Global, by End Point Status, 2015* 23
Neurotoxicity Syndromes Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2010-2014 24
Neurotoxicity Syndromes Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2015* 25
Neurotoxicity Syndromes Therapeutics Clinical Trials, Global, Key Sponsors, 2015* 26
Neurotoxicity Syndromes Therapeutics Clinical Trials, Global, Top Companies by Phase, 2015* 27
Neurotoxicity Syndromes Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2015* 28

List of Figures
Neurotoxicity Syndromes Therapeutics, Global, Clinical Trials by Region (%), 2015* 6
Neurotoxicity Syndromes Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2015* 7
Neurotoxicity Syndromes Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2015* 9
Neurotoxicity Syndromes Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2015* 10
Neurotoxicity Syndromes Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2015* 11
Neurotoxicity Syndromes Therapeutics Clinical Trials, North America, Top Countries (%), 2015* 12
Proportion of Neurotoxicity Syndromes to Central Nervous System Clinical Trials, G7 Countries (%), 2015* 14
Neurotoxicity Syndromes Therapeutics, G7 Countries, Clinical Trials by Phase, 2015* 15
Neurotoxicity Syndromes Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2015* 16
Proportion of Neurotoxicity Syndromes to Central Nervous System Clinical Trials, E7 Countries (%), 2015* 17
Neurotoxicity Syndromes Therapeutics, E7 Countries, Clinical Trials by Phase, 2015* 18
Neurotoxicity Syndromes Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2015* 19
Neurotoxicity Syndromes Therapeutics, Global, Clinical Trials by Phase (%), 2015* 20
Neurotoxicity Syndromes Therapeutics, Global, Clinical Trials In Progress by Phase, 2015* 21
Neurotoxicity Syndromes Therapeutics, Global, Clinical Trials by Trial Status, 2015* 22
Neurotoxicity Syndromes Therapeutics Clinical Trials, Global, by End Point Status, 2015* 23
Neurotoxicity Syndromes Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2010-2014 24
Neurotoxicity Syndromes Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2015* 25
Neurotoxicity Syndromes Therapeutics Clinical Trials, Global, Key Sponsors, 2015* 26
Neurotoxicity Syndromes Therapeutics Clinical Trials, Global, Top Companies by Phase, 2015* 27
Neurotoxicity Syndromes Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2015* 28
GlobalData Methodology 70

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *

Upcoming Reports

  • Bio-services Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2012 - 2018

    Bio-services involve preclinical and clinical researches done by following the standards laid down by regulatory bodies. Clinical research organizations (CRO) segment their researches by contracts, manufacturing, and clinical trials. A clinical trial is a time consuming process, and specifies testing of the new drugs on specific people or for particular diseases. CRO can be divided into captive and independent. The former involves developin...

  • Ethical Pharmaceuticals Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2014 - 2020

    Ethical pharmaceuticals or prescription drugs are those licensed drugs that are regulated by various legislations to require a written medical prescription before it can be procured. An ethical pharmaceutical product is only sold by a pharmacists when it has been approved by a written medical prescription from a registered medical practitioner. The term prescription drugs or ethical pharmaceutical is usually used to distinguish the products from ...

  • Next Generation Sequencers Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2019

    Next generation sequencers are used inthe sequencing technologies which massively parallelize the DNA sequencing process rather than being limited to single or few fragments of DNA. The next generation sequencing (NGS) technology enables rapid sequencing and produce thousands and millions of sequences in single run with the use of next generation sequencers. Such technologies have been rapidly developing owing to continuous demand for high-thro...